OUR SCIENCE
A new generation of therapies
miragene pipeline
BTK
(3rd-gen BTKi with once-daily potential)
Chronic spontaneous urticaria
Other indications to be disclosed
Two targets to be disclosed
(bi-specific mAb with extended half-life)
To be disclosed
led by Partners
ILT7
(mAb)
To be disclosed
IL7Ra
(mAb)
To be disclosed
*Formed partnership with Aditum Bio to create Celexor
Bio
+Global rights out-licensed to Ornovi
Inc.
MAG-007
a potent, highly selective, noncovalent, reversible BTK inhibitor
MAG-007 is a noncovalent, reversible, and highly selective oral inhibitor of Bruton’s tyrosine kinase (BTK), specifically designed for the treatment of inflammatory and autoimmune diseases that often require long-term therapy. It is brain-permeable and exhibits potent activity. In Phase 1 studies in healthy adults, MAG-007 demonstrated a favorable safety profile, extended half-life, and durable pharmacodynamic effects—supporting the potential for once-daily (QD) dosing. The program is now ready to advance into Phase 2 development.
QuadraTek®:
a platform for innovation
Our proprietary QuadraTek® platform is designed to create highly differentiated biologic drug candidates with the potential to better address unmet needs in immunologic and inflammatory diseases.
Four parallel systems to generate diversified, high-performing leads
Proprietary functional assays to select competitive, differentiated drug candidates
Advanced protein engineering to optimize different aspects of a product
